Generate Biomedicines, Inc.
NASDAQGenerate Biomedicines has delivered one of biotech's standout weeks, gaining 27% in seven days and 52% over the past month — yet the stock still trades below most analyst targets, and the borrow market shows no meaningful squeeze pressure behind the move. The Street entered this week constructively positioned. When GENB went public earlier this year, it drew immediate Buy-side…
GENB short interest surges 58% in one week to 3.16M shares, now at 43.1 ORTEX short score following positive analyst revisions.
Snapshot as of 29 Sept 2026
Generate Biomedicines has delivered one of biotech's standout weeks, gaining 27% in seven days and 52% over the past month — yet the stock still trades below most analyst targets, and the borrow market shows no…
Generate Biomedicines has put together one of the cleaner biotech rallies of the past month, gaining 29% since early June, yet the borrow market tells a more cautious story beneath the surface. The most telling shift…
Generate Biomedicines has rarely been noisier. The stock is up 17% on the week, short sellers are piling in at the fastest pace since listing, and Nvidia just revealed a fresh stake — all at the same time. The short…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for GENB — free to start on ORTEX.
Sign up for free →Open GENB on ORTEX